



Study to tackle unresolved link between prostate cancer treatment and cardiovascular disease Movember Foundation and Prostate Cancer Canada team up to award \$3+ million grant

TORONTO, ON (April 15, 2015) - Funded by the Movember Foundation and selected by Prostate Cancer Canada (PCC), Dr. Jehonathan Pinthus and his team will directly address the longstanding uncertainty regarding a connection between Androgen Deprivation Therapy (ADT) – an important and common treatment for prostate cancer – and an increased risk of cardiovascular disease. The project will receive up to \$3.5 million over five years after winning the Movember Clinical Trials grant competition, which sought proposals that were focused on minimizing burdens associated with prostate cancer treatment.

“By eliminating testosterone production, ADT reduces the risk of death and other complications from prostate cancer,” explained Pinthus. “However, secondary data from many past studies that were focused on separate hypotheses have both raised and dismissed concerns that ADT causes heart disease in otherwise healthy subjects and/or exacerbates it in subjects with preexisting conditions.”

“We’re very proud to be funding the Clinical Trials program,” said Pete Bombaci, Country Director, Movember Canada. “This program aims to improve the lives of men suffering from the effects of advanced prostate cancer treatment, and our goal is to accelerate breakthroughs in prostate cancer research that patients can benefit from in their everyday lives.”

Dr. Pinthus’ work will be the first to make this topic the primary study focus, and, in so doing, will provide unprecedented insight that will inform patient management practices to mitigate risk for men being treated with ADT. An Associate Professor in the Department of Surgery, Division of Urology at McMaster University and Surgical Oncologist at Hamilton Health Sciences, Dr. Pinthus will lead a multi-disciplinary team of researchers across multiple sites in Canada with expertise in cardiology, endocrinology and metabolism, urology-oncology, radiation oncology and epidemiology. The project’s co-investigators are Dr. Laurence Klotz, Sunnybrook Health Sciences Centre, Dr. Darryl Leung, McMaster University/Hamilton Health Sciences, and Dr. Himu Lukka, McMaster University/Hamilton Health Sciences.

“In men with metastatic or advanced stage prostate cancer, ADT has demonstrated a great deal of efficacy in saving and extending lives,” reinforced PCC Vice President of Research, Health Promotion and Survivorship, Dr. Stuart Edmonds. “In order to make this important treatment as safe as possible, we need to clearly understand the cardiovascular side-effects and develop a comprehensive plan to monitor and manage them. This study aims to do just that.”

-30-

For media inquiries, please contact:

Alex Shaw
alex@getfreshpr.com
604 655 1462

About Prostate Cancer Canada

Prostate Cancer Canada develops, offers and funds innovative programs related to awareness and public education, advocacy, support of those affected, and research into the prevention, detection, treatment and cure of prostate cancer. For more information please visit prostatecancer.ca.

About The Movember Foundation

The Movember Foundation's vision is to have an everlasting impact on the face of men's health. We do this by getting men to grow moustaches during Movember (the month formerly known as November) to spark conversation and raise funds for prostate cancer, testicular cancer and mental health. Together with the Movember community we have raised more than \$600 million CAD, and have funded more than 800 world-class programs in 21 countries. We're committed to

changing the face of men's health and won't stop growing as long as serious men's health issues remain. Movember is a registered charity in Canada - BN 848215604 RR0001. For more information visit Movember.com.